Sign in to view content

Safety, Tolerability, and Efficacy of Tinlarebant: 24-Month Primary Outcomes of the Phase 2 Study in Adolescent Patients With Stargardt Disease

Quan Dong Nguyen, MD, MSc, FARVO, FASRS

Video
Published 2024

Related

Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Arshad M. Khanani, MD, MA, FASRS
Updates from the Field
2022
APX3330, an Oral Drug in Trial for DR and DME, Demonstrated a Favorable Safety and Tolerability Profile in Multiple Phase 1 and 2 Studies
Michael J Allingham, MD, PhD
Annual Meeting Talks
2021
Update From an Ongoing Phase 1b/2 Open-label Clinical Trial Evaluating the Safety and Efficacy of AU-011 for the Treatment of Choroidal Melanoma
Ivana K. Kim, MD
Annual Meeting Talks
2020

Category: Hereditary Retinal Disease & Genetics

See more